The challenge of antimicrobial resistance (AMR): current status and future prospects
Naunyn-Schmiedeberg's Archives of Pharmacology · 2024-12 · 397 (12) · 9603-9615
DOI: 10.1007/s00210-024-03318-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 25.07.2024. Verfasst von Francesco Ferrara und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Department, Asl Napoli 3 Sud, Dell'amicizia Street 72, 80035, Nola, Naples, Italy. f.ferrara@aslnapoli3sud.it. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Resistance, Bacterial. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 89 Literaturangaben.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) represents a critical global threat, compromising the effectiveness of antibacterial drugs as bacteria adapt and survive exposure to many classes of these drugs. This phenomenon is primarily fueled by the widespread overuse and misuse of antibacterial drugs, exerting selective pressure on bacteria and promoting the emergence of multi-resistant strains. AMR poses a top-priority challenge to public health due to its widespread epidemiological and economic implications, exacerbated not only by the diminishing effectiveness of currently available antimicrobial agents but also by the limited development of genuinely effective new molecules. In addressing this issue, our research aimed to examine the scientific literature narrating the Italian situation in the common European context of combating AMR. We sought to delineate the current state of AMR and explore future prospects through an analysis of strategies to counter antibacterial drug resistance. Adopting the "One Health" model, our objective was to comprehensively engage diverse sectors, integrate various disciplines, and propose programs, policies, and regulations. This narrative review, based on PubMed research related to antibiotic resistance, emphasizes the urgent need for a coordinated and proactive approach at both national and European levels to mitigate the impact of AMR and pave the way for effective strategies to counter this global health challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Department, Asl Napoli 3 Sud, Dell'amicizia Street 72, 80035, Nola, Naples, Italy. f.ferrara@aslnapoli3sud.it.
- Pharmacy Unit, ASST Di Lecco, Dell'Eremo Street 9/11, 23900, Lecco, Italy.
- University of Milan, Festa del Perdono Street 7, 20122, Milan, Italy.
- Fondazione IRCCS Istituto Nazionale Tumori, Giacomo Venezian Street 1, 20122, Milan, Italy.
- IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, 20159, Milan, Italy.
- Istituto Europeo Di Oncologia, Ripamonti Street 435, 20122, Milan, Italy.
Zitieren
APA
Ferrara, F., Castagna, T., Pantolini, B., Campanardi, M. C., Roperti, M., Grotto, A., Fattori, M., Dal Maso, L., Carrara, F., Zambarbieri, G., Zovi, A., Capuozzo, M., & Langella, R. (2024). The challenge of antimicrobial resistance (AMR): current status and future prospects. Naunyn-Schmiedeberg's Archives of Pharmacology, 397(12), 9603-9615. https://doi.org/10.1007/s00210-024-03318-x
Vancouver
Ferrara F, Castagna T, Pantolini B, Campanardi MC, Roperti M, Grotto A, et al. The challenge of antimicrobial resistance (AMR): current status and future prospects. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024;397(12):9603-9615. doi:10.1007/s00210-024-03318-x
BibTeX
@article{Ferrara2024,
author = {Ferrara, Francesco and Castagna, Tommaso and Pantolini, Beatrice and Campanardi, Maria Chiara and Roperti, Martina and Grotto, Alessandra and Fattori, Martina and Dal Maso, Lucia and Carrara, Federica and Zambarbieri, Giulia and Zovi, Andrea and Capuozzo, Maurizio and Langella, Roberto},
title = {The challenge of antimicrobial resistance (AMR): current status and future prospects},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2024},
volume = {397},
number = {12},
pages = {9603--9615},
doi = {10.1007/s00210-024-03318-x}
}
EUVIMED